Biomoda Inc. Gets Nod from U.S. Patent Office; Detection of Precancerous Conditions is Targeted by Biomoda Researchers.

ALBUQUERQUE, N.M. -- The U.S. Patent Office issued its Formal Notice of Allowance for a Patent developed by Biomoda researchers titled "Compositions and Methods for Detecting Precancerous Conditions in Cells and Tissue Samples using 5, 10, 15, 20 Tetrakis (Carboxyphenyl) Porphine." This patent brings a significant addition to Biomoda's patent portfolio and expands the company's intellectual property to include cancer screening as a complement to Biomoda's existing technology.

Biomoda is completing the formal filing for a continuation for this patent based on research currently underway by researchers at Biomoda. The company believes its goal to further strengthen and expand its intellectual property portfolio will be significantly enhanced by these developments.

Biomoda Inc., a development stage in-vitro diagnostics organization, is focused on research, development and commercialization of cancer diagnostics. The company, exclusive worldwide licensee from the University of California of several patents developed for noninvasive early detection and treatment of lung cancer, is in the process of registering additional patents in this area. The company's proprietary technologies provide minimally invasive and minimal impact approaches as cancer diagnostic products. Operating from its laboratory situated at Kirtland Air Force Base (Albuquerque, N.M.), the company is in the process of expanding and expediting its product development and commercialization with a number of strategic alliances that will be announced over the next 60 days.

This news release contains forward-looking statements that involve a high degree of risk and uncertainty. Such statements include, but are not limited to, statements containing the words "believes," "anticipates," "expects," "estimates" and words of similar import. The company's actual results could differ materially from any forward-looking statements, which reflect management's opinions only as of the date of this report, as a result of risks and uncertainties that exist in our operation, development efforts and business environment. The company undertakes no obligation to revise or publicly release the results of any revisions to these forward-looking statements. You should carefully review the risk factors in other documents that the company files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. For additional information, visit the Biomoda Web site at www.biomoda.com or call us at 505-821-0875.